Dual antiplatelet therapy consisting of aspirin in combination with clopidogrel, ticagrelor, or prasugrel is considered the standard of care for preventing stent thrombosis following percutaneous coronary angioplasty. However, adverse cardiovascular events may still occur despite such biotherapy. This can be explained by resistance to antiplatelet agents, with clopidogrel resistance the most widely studied so far. Some cases of resistance to other antiplatelet agents like prasugrel and ticagrelor have recently been reported. While laboratory tests have been developed to assess the degree of platelet inhibition under treatment, their clinical usefulness remains controversial. We herein report the case of a patient with a resistance to different antiplatelet agents.
Antiplatelets agents, resistance, clopidogrel, Multiplate analyzer